Tempest Therapeutics (NASDAQ:TPST) Issues Quarterly Earnings Results

Tempest Therapeutics (NASDAQ:TPST) released its earnings results on Thursday. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04), FiscalAI reports.

Tempest Therapeutics Price Performance

TPST stock traded down $0.04 during midday trading on Thursday, hitting $1.17. The stock had a trading volume of 277,052 shares, compared to its average volume of 182,246. The business has a 50-day moving average of $1.07 and a two-hundred day moving average of $1.72. The firm has a market cap of $18.70 million, a price-to-earnings ratio of -0.19 and a beta of -1.72. Tempest Therapeutics has a 52-week low of $0.84 and a 52-week high of $12.23.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on TPST. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Monday, July 13th. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Wall Street Zen cut shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Tempest Therapeutics stock. Vanguard Group Inc. grew its holdings in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 162,560 shares of the company’s stock after purchasing an additional 27,952 shares during the period. Vanguard Group Inc. owned approximately 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent SEC filing. 22.52% of the stock is owned by hedge funds and other institutional investors.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.